GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Charles Bancroft | |||
| b) | Position/status | Senior Independent Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Release of 17,446 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,602 notional ADSs for tax and the final release of 15,843 ADSs representing the balance. These ADSs will be held by Charles Bancroft until he retires from the Board. A residual cash payment of $32.60 will be paid to Charles Bancroft. | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $38.805 | 15,843 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-03-25 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Anne Beal | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Release of 1,988 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 1,018 notional ADSs for tax and the final release of 970 ADSs representing the balance. These shares will be held by Dr Anne Beal until she retires from the Board. A residual cash payment of $4.66 will be paid to Dr Anne Beal.
| |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $38.805 | 970 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-03-25 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Hal Dietz | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Release of 1,760 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 909 notional ADSs for tax and the final release of 850 ADSs representing the balance. These shares will be held by Dr Hal Dietz until he retires from the Board. A residual cash payment of $38.42 will be paid to Dr Hal Dietz. | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $38.805 | 850 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-03-25 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr Jesse Goodman | |||
| b) | Position/status | Independent Non-Executive Director | |||
| c) | Initial notification/ amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Release of 13,924 notional ADSs from the GSK Non-Executive Director Share Allocation Arrangements following the termination of those arrangements, the withholding of 7,082 notional ADSs for tax and the final release of 6,842 ADSs representing the balance. These shares will be held by Dr Jesse Goodman until he retires from the Board. A residual cash payment of $11.64 will be paid to Dr Jesse Goodman. | |||
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $38.805 | 6,842 | | ||
| | | | | ||
| d) | Aggregated information
| N/A (single transaction) | |||
| Aggregated volume Price | | ||||
| e) | Date of the transaction | 2025-03-25 | |||
| f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
